Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05600114 · ClinicalTrials.gov registry record · Phase 2
Cannabidiol (CBD) for the Treatment of Social Anxiety Disorder
A Phase 2 study of Social Anxiety Disorder, sponsored by EmpowerPharm.
- Completed
- Registry status
- Phase 2
- Development phase
- 239
- Enrollment target
- 17
- Study locations
NCT05600114 is a Phase 2 study of Social Anxiety Disorder that has completed, run by EmpowerPharm. The registered enrollment target is 239 participants, above the 153-participant average among 32 other Social Anxiety Disorder trials with a reported enrollment target (56% higher). The trial reports 17 study locations across 8 states.
The verdict
NCT05600114, a Phase 2 study of Social Anxiety Disorder, has completed, sponsored by EmpowerPharm.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 239 participants
- Enrollment target
- 17
- Study locations
Study Summary
A phase 2, multicenter, double-blind, parallel group, placebo-controlled, randomized clinical study, designed to compare the efficacy, safety, and tolerability of 2 dose levels of CBD and a matching placebo for the treatment of subjects with Social Anxiety Disorder (SAD).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Cannabidiol oral solution
Study Locations (17)
California
- EPI-CBD-001 Site - Encino
- EPI-CBD-001 Site - Lemon Grove
- EPI-CBD-001 Site - Los Alamitos
- EPI-CBD-001-Site - Oceanside
- EPI-CBD-001 site - San Jose
Florida
- EPI-CBD-001 Site - Jacksonville
- EPI-CBD-001 Site - Lauderhill
- EPI-CBD-001 Site - Maitland
- EPI-CBD-001 Site - Orlando
New York
- EPI-CBD-001 Site - Cedarhurst
- EPI-CBD-001-Site - New York
- EPI-CBD-001-Site - Rochester
Illinois
- EPI-CBD-001 Site - Chicago
Oklahoma
- EPI-CBD-001 Site - Oklahoma City
Oregon
- EPI-CBD-001 Site - Portland
Texas
- EPI-CBD-001 site - Wichita Falls
Washington
- EPI-CBD-001 Site - Bellevue
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 239 participants |
| Start Date | 2022-10-27 |
| Est. Completion | 2023-12-13 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05600114
The ClinicalTrials.gov registry entry for NCT05600114 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 239 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 153-participant average among 32 other Social Anxiety Disorder trials with a reported enrollment target (56% higher). The listed sponsor is EmpowerPharm, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Social Anxiety Disorder appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05600114 reports 17 study locations spanning 8 distinct geographic areas - top geographies include California, Florida, New York.
Frequently Asked Questions
What is clinical trial NCT05600114 about?
NCT05600114 is a clinical study titled "Cannabidiol (CBD) for the Treatment of Social Anxiety Disorder". A phase 2, multicenter, double-blind, parallel group, placebo-controlled, randomized clinical study, designed to compare the efficacy, safety, and tolerability of 2 dose levels of CBD and a matching placebo for the treatment of subjects with Social Anxiety Disorder (SAD).
What is the current status of trial NCT05600114?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 239 participants. The study started on 2022-10-27. Estimated completion is 2023-12-13.
What conditions does trial NCT05600114 study?
This clinical trial studies the following conditions: Social Anxiety Disorder.
What interventions are being tested in trial NCT05600114?
The interventions under investigation include: Placebo (DRUG), Cannabidiol oral solution (DRUG).
Who is sponsoring clinical trial NCT05600114?
This trial is sponsored by EmpowerPharm, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05600114 being conducted?
This trial has 17 study locations across California, Florida, Illinois, New York, Oklahoma. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Social Anxiety Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Clinical Trial to Assess the Efficacy, Safety, and Tolerability of a Repeat Dose of Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder
RECRUITING · Phase 2
-
Cannabidiol as a Treatment for Social Anxiety Disorder (R61)
COMPLETED · Phase 2
-
Validating an Autonomous Interactive Internet-Based Delivery of an Empirically Supported Cognitive Behavioral Therapy for Comorbidity
RECRUITING · NA
-
Individual Factors of CBT Underlying Success
RECRUITING · NA
-
Neurofeedback Enhanced Cognitive Reappraisal Training - Phase 4
RECRUITING · NA
-
Very Brief Exposure: Development of a Novel Exposure Modality for Social Anxiety Disorder in Transition-Age Youth
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.